Analysis of Differences in Sunscreen Use Based on Demographic Variables Using the NHANES Database

A 24-year-old male experiencing diffused thinning discusses his DHT levels and hair density issues. He has not used finasteride or dutasteride and is considering AR inhibitors.

The conversation discusses using very low dose topical finasteride to achieve specific serum DHT reduction percentages. It concludes that finasteride dosage increases linearly between 5-30% DHT reduction but requires exponential increases for reductions up to 70%.

The user added dutasteride once a week for three months and shared blood work results, noting low vitamin D. Another user mentioned experiencing hair thinning while on the same treatment.

Topical finasteride may have higher systemic absorption and lower efficacy when using a Propylene Glycol/Ethanol formulation compared to the hydroxypropyl chitosan (HPCH) formulation. The safety profile of topical finasteride relies heavily on the HPCH formulation, and using standard solutions might lead to different pharmacokinetics.

The user is applying 0.4 mg of finasteride and 4 mg of minoxidil daily through a topical solution. This corresponds to a specific dosage analysis for hair loss treatment.

The user has been mixing finasteride with stemoxydine for hair loss and is considering switching to a less expensive product with a different ingredient list. They are questioning if the new product's higher water content compared to alcohol will affect the finasteride's solubility.